[SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
The Multiple Outcomes of Raloxifene Evaluation (MORE) Trial enrolled 7,705 women with osteoporosis, defined by prevalent vertebral fractures and/or a bone mineral density (BMD) T score at -2.5 or below, who were treated with placebo or raloxifene at a dosage of 60 or 120 mg/day for 3 years. Raloxifene hydrochloride therapy significantly reduces the risk for vertebral fractures at 3 and 4 years administration group. The fact that Raloxifene administration causes the significant 25% reduction in overall risks in postmenopausal women indicate a favorable risk-benefit profile. These data suggested that raloxifene is effective to protect from the occurrence of bone fracture without causing increases of breast cancer and endometrial cancer, and improve overall health conditions in postmenopausal women.
Inaba
Masaaki
M
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
D015519:Bone Density; D004550:Elbow / Q000503:physiopathology; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects; D016103:Spinal Fractures / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride